Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

About this update from Tevogen Bio Holdings Inc.

WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including the near completion of its PredicTcell™ training algorithm and early steps toward commercial readiness. PredicTcell™, Tevogen.AI’s proprietary machine learning model designed to identify immunologically active peptides, is approaching the final stages of its training phase. The model has been trained on one of the industry’s largest curated peptide datasets, with feature expansion now exceeding 180 parameters, contributing to an approximate 10% improvement in precision. As development progresses, the Company has begun evaluating potential co-development partnerships to support broader application of the platform. These efforts are grounded in addressing a fundamental challenge in drug development, high-confidence target identification, which today often requires significant wet lab validation. By leveraging advanced predictive modeling, Tevogen.AI aims to reduce development timelines, material costs, and overall experimental burden. To support this transition, Tevogen.AI has developed an initial version of an internal application and portal designed to serve the PredicTcell™ model in a scalable and user-friendly environment. This system is intended to streamline internal workflows while also serving as the foundation for a potential future customer-facing platform. “Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “As we begin exploring commercial pathways, our focus remains on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.” About Tevogen Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system. Tevogen Bio, the company’s lead initiative, has completed...

View stock analysis, news, and events for Tevogen Bio Holdings Inc.